2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2981

Prospective Cohort of Surgically-Diagnosed Aortitis at the Ottawa Hospital

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2797

Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2269

Proteinaceous Amorphous Calcium Carbonates As a Novel Family of Crystals in Synovial Fluid from Symptomatic Joints

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2770

Psoriatic Arthritis Limits Patients’ Abilities to Undertake Activities Crucial for Normal Daily Life and Impacts Happiness, Results from a Multinational Real-World Sample

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2978

Psychiatric Involvement and Behcet’S Syndrome: Does Bipolar Disorder Represent a Clinical Feature of the Disease?

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2692

Pulmonary Involvement, As Part of the Essdai, in Primary Sjogren’s Syndrome

Sjögren's Syndrome - Poster II: Clinical Science

9:00AM-11:00AM: Abstract Number: 2570

Pyruvate Regulates Reactive Oxygen Species (ROS) Production, Dysfunction and Aberrant Metabolism of Mitochondria in Fibroblast-like Synoviocytes of Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster III

9:00AM-11:00AM: Abstract Number: 2547

Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2238

RA Medication Preferences Among U.S. Patients in an Online Rheumatoid Arthritis Community

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2351

Racial Differences in Magnetic Resonance Image-Based Three-Dimensional Bone Shape of the Knee: Data from the Osteoarthritis Initiative (OAI)

Osteoarthritis – Clinical Aspects - Poster II

9:00AM-11:00AM: Abstract Number: 2501

Radiographic Damage in Patients with RA Increases By 8.3% per Year Disease Duration, in the Era of Biologic Dmards. Results from the Scqm Cohort

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2350

Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee

Osteoarthritis – Clinical Aspects - Poster II

9:00AM-11:00AM: Abstract Number: 2534

Radiographic Remission in Patients with Seropositive RA at Ten Years after Diagnosis, Treated in a Real Life Setting

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2353

Radiographic Variations in Hip Morphology Are Associated with Hip Symptoms: A Cross-Sectional Analysis of a Large Community-Based Cohort

Osteoarthritis – Clinical Aspects - Poster II

9:00AM-11:00AM: Abstract Number: 2398

Reaching the Masses: A Novel Approach to Pediatric Rheumatology Education Via Tele-Learning

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].